BioMarin Pharmaceutical (BMRN) Competitors

Alnylam Pharmaceuticals (NASDAQ:ALNY) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

Which has more risk & volatility, ALNY or BMRN?

Alnylam Pharmaceuticals has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500.

Do analysts recommend ALNY or BMRN?

Alnylam Pharmaceuticals currently has a consensus target price of $340.00, suggesting a potential upside of 2.43%. BioMarin Pharmaceutical has a consensus target price of $93.61, suggesting a potential upside of 63.51%. Given BioMarin Pharmaceutical's higher possible upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Alnylam Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.79
BioMarin Pharmaceutical	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.75

Does the media favor ALNY or BMRN?

In the previous week, Alnylam Pharmaceuticals had 10 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 21 mentions for Alnylam Pharmaceuticals and 11 mentions for BioMarin Pharmaceutical. Alnylam Pharmaceuticals' average media sentiment score of 0.99 beat BioMarin Pharmaceutical's score of 0.97 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	12 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger earnings and valuation, ALNY or BMRN?

BioMarin Pharmaceutical has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$2.25B	19.25	-$278.16M	-$2.09	-158.82
BioMarin Pharmaceutical	$2.85B	3.85	$426.86M	$2.69	21.28

Do institutionals and insiders have more ownership in ALNY or BMRN?

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 0.9% of BioMarin Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Is ALNY or BMRN more profitable?

BioMarin Pharmaceutical has a net margin of 17.76% compared to Alnylam Pharmaceuticals' net margin of -11.49%. BioMarin Pharmaceutical's return on equity of 11.34% beat Alnylam Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	-11.49%	-510.31%	-6.48%
BioMarin Pharmaceutical	17.76%	11.34%	8.95%

Summary

BioMarin Pharmaceutical beats Alnylam Pharmaceuticals on 9 of the 16 factors compared between the two stocks.